OXBOF (Oxford BioDynamics) Tax Expense: $-0.36 Mil (TTM As of Sep. 2025)


What is Oxford BioDynamics Tax Expense?

Oxford BioDynamics OXBOF -33.33% Tax Expense is $-0.36 Mil as of Sep. 2025. The stock has 4 warning signs investors should review.

Oxford BioDynamics's tax expense for the months ended in Sep. 2025 was $-0.17 Mil. Its tax expense for the trailing twelve months (TTM) ended in Sep. 2025 was $-0.36 Mil.


Oxford BioDynamics  (OTCPK:OXBOF) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Oxford BioDynamics Tax Expense Related Terms


Oxford BioDynamics Tax Expense Historical Data

* Premium members only.

The historical data trend for Oxford BioDynamics's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oxford BioDynamics Tax Expense Chart

Oxford BioDynamics Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.30 -0.97 -0.72 -0.52 -0.36

Oxford BioDynamics Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.34 -0.19 -0.32 -0.18 -0.17

Oxford BioDynamics Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Expense →
What does a Tax Expense of $-0.36 Mil mean?
Oxford BioDynamics (OXBOF) has a Tax Expense of $-0.36 Mil as of Sep. 2025. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Oxford BioDynamics and its competitors.
Is Oxford BioDynamics' Tax Expense too high?
Oxford BioDynamics' current Tax Expense is $-0.36 Mil.
How does Oxford BioDynamics' Tax Expense compare to TMO and DHR?
Oxford BioDynamics' Tax Expense of $-0.36 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Expense for a Medical Diagnostics & Research company?
A good Tax Expense depends on the Medical Diagnostics & Research industry context. However, Tax Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Expense mean?
A high Tax Expense can signal that a stock is expensive relative to its fundamentals. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Oxford BioDynamics and its competitors. Oxford BioDynamics's current Tax Expense is $-0.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioDynamics stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioDynamics (OXBOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.06, compared to a current price of $0.00 — trading 96.7% below its estimated fair value. The current Tax Expense is $-0.36 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Expense calculated?
Tax Expense is calculated from a company's financial statements. For Oxford BioDynamics (OXBOF), the current Tax Expense is $-0.36 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oxford BioDynamics Business Description

Other Exchanges OBD:UKLMQ:Germany
Address John Smith Drive, 3140 Rowan Place, Oxford Business Park South, Oxford, GBR, OX4 2WB
Oxford BioDynamics PLC is a biotechnology company focused on advancing personalized healthcare through the development and commercialization of precision medicine tests for serious and impactful diseases. The company is engaged in the commercialisation of proprietary molecular diagnostics products and biomarker research and development. It has two commercially available products: the EpiSwitch PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test) blood tests. The company generates revenue from the sales of proprietary products and biomarker research and development. Geographically, it generates the maximum revenue from the USA.